Menu fechado
Informações Gerais
Disciplina optativa com carga horária de 20h.
Ementa
  • Diversidade populacional e variabilidade na resposta Terapêutica/ toxicidade;
  • Fenotipagem e Genotipagem;
  • Transportadores e alvos terapêuticos;
  • Aplicações da farmacogenética em Cardiologia / Pneumonologia;
  • Aplicações da farmacogenética em Imunologia / Oncologia;
  • Aplicações da farmacogenética em Psiquiatria / Neurologia;
  • Aplicações da farmacogenética em Hematologia / Reumatologia;
  • Aspectos éticos e sociais da farmacogenética.
  • Epigenética e a variabilidade da resposta a fármacos;
  • Farmacogenômica e o Desenvolvimento de Fármacos;
Bibliografia Básica
  • WENDELL, W. Pharmacogenetics (Oxford Monographs on Medical Genetics), 2ª edição.
  • BERTINO, J. S. Pharmacogenomics An Introduction and Clinical Pespective, 1ª edição.
  • KUMAR, D.; ENG, C. Genomic Medicine: Principles and Practice (Oxford Monographs on Medical Genetics).
Bibliografia Complementar
  • BJORKMAN, S. Prediction of cytochrome P450- mediated hepatic drug clearance in neonates, infants and children. ClinPharmacokinet, v.45, n.l, p.l-ll, 2006.
  • BOSCH, T. M.; MEIJERMAN, I.; BEUNEN, J. H.; SCHELLENS, H. M. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. ClinPharmacokinet, v.45, n.3, p.253-285, 2006.
  • BROOS, A. J. The essence of SNPs. Gene. 1999. 234:177-186.
  • DAIÍL, M. L. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? ClinPharmacokinet. 2002. 41:453-470.
  • DAHL, M. L. Cytochrome P450. Phenotyping/Genotyping in patients receiving antipsychotics. ClinPharmacokinet, v. 41, n. 7, p. 453-470, 2002.
  • DESTA, Z.; ZHAO, X.; ,SHIN, J. G; FLOCKHART, D. A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. ClinPharmacokinet, v. 41, n. 12, p. 913-958, 2002.
  • EVANS, W. E. JOHNSON, J. A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev. Genomics Hum Genet., v. 2, p. 9-39, 200l.
  • INGELMAN-SUNDBERG, M.; OSCARSON, M.; MCLELLAN, R. A. Polyrnorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci. 1999; 20:342-349.
  • INGELMAN-SUNDBERG, M. Polymorphism to cytochrome P450 and xenobiotic toxicity. Toxicology, V. 181-182, p. 447-452, 2002.
  • LINDPAINTNER, K. The impact of pharmacogenetics and pharmacogenomics on drug discovery. Nat Rev Drug Discov. 2002; 1:463-469.
  • MCLEOD, H. L, EVANS, W. E. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev PharmacolToxicol. 2001;41:101-121.
  • MUKHERJEE, D.; TOPOL, E. Pharmacogenomics in cardiovascular diseases. ProgCardiovasc Dis. 2002;44:479-498.
  • ROWLAND, M.; TOZER, T. N. Clínical Pharmacokinetics and Pharmacodynamics: concepts and applications, 4ª edição. Lippincott, Williams & Wilkins, 839 p., 2011.
  • SAKAEDA, T. MDR Genotype-related pharmacokinetics: fact or fiction? Drug MetabPharmacokinet, v.20, n.6, p.391-414, 2005.
  • TANAKA, E.; KURATA, N.; YASUHARA, H. How useful is the “cocktail approach” for evaluating hurnan hepatic drug metábolizing capacity using cytochrome P450 phenotyping probes in vivo? Joumal of Clinical Pharmacy and Therapeutics, V. 28, p. 157-165,2003.
  • ZHANG, Y.; BENET, L. Z. The gut as a barrier to drug absorption: combined role of cytochrome P4503A and P-glycoprotein. ClinPharmacokinet, v.40, n. 3, p. 159-168, 2001.